Telomir-Zn Preclinical Data Published: Iron-Dependent Mechanism Suppresses TNBC and Prostate Tumors, Phase 1/2 Trial Planned
TELO sits 35% above its 52-week low of $0.888 on light trading volume (0.1× avg).
Summary
Telomir Pharmaceuticals published preclinical data demonstrating Telomir-Zn's iron-dependent anti-cancer mechanism in TNBC and prostate cancer models, with plans to initiate a Phase 1/2 trial. The findings support a novel therapeutic approach in difficult-to-treat cancers.
Key Events · Product Development and Regulatory · TELO
-
Preclinical Data Published
A peer-reviewed study in the Journal of Oncology Research and Therapy shows that Telomir-Zn inhibits histone demethylases by depleting intracellular iron, reactivating tumor-suppressor genes and reducing tumor growth in TNBC and prostate cancer models.
-
Iron-Dependent Mechanism Confirmed
Iron-rescue experiments reversed Telomir-Zn's anti-cancer effect, proving the mechanism is specific and not due to general toxicity. At low concentrations, the compound selectively killed cancer cells while sparing normal cells.
-
Anti-Metastatic Activity Demonstrated
In an HCC1806 TNBC model, Telomir-Zn significantly reduced metastatic dissemination, addressing a key cause of mortality in TNBC patients. Combining it with paclitaxel showed synergistic tumor reduction.
-
Phase 1/2 Clinical Trial Planned
The company intends to advance Telomir-Zn into a Phase 1/2 trial in TNBC under an active IND, with potential for patient stratification based on iron-metabolism biomarkers.
Analysis · TELO · Life Sciences
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing that its lead candidate, Telomir-Zn, suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models by depleting intracellular iron—a mechanism confirmed by iron-rescue experiments. The compound reactivated silenced tumor-suppressor genes and reduced metastatic spread in an aggressive TNBC model. With an active IND in hand, the company plans to advance into a Phase 1/2 clinical trial in TNBC. For a micro-cap biotech, this represents significant scientific validation, providing a mechanistic rationale for a planned trial in an area of high unmet need. The news could positively influence investor perception of the pipeline, though clinical success remains uncertain.
At the time of this filing, TELO was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.89 to $2.09. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.